Ophthalmic gene therapy company Beacon Therapeutics has raised USD 170 million in a Series B funding round led by Forbion with participation from Syncona Limited, Oxford Science Enterprises, the University of Oxford, TCGX, and Advent Life Sciences.
The new funds are expected to accelerate the clinical development of its lead candidate, AGTC-501, for X-linked retinitis pigmentosa (XLRP).
UK-based Beacon Therapeutics is dedicated to restoring and improving vision for patients suffering from a range of prevalent and rare retinal diseases. The company leverages its proprietary gene therapy technologies to address multiple conditions, including X-linked retinitis pigmentosa (XLRP), dry age-related macular degeneration (AMD), and cone-rod dystrophy (CRD).
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.